Back to Articles
Performance November 18, 2026 22 min read5,292 words

ACE-031 | Buy Online | Muscle Wasting Research Guide

ACE-031 traps myostatin and activins to drive extraordinary muscle growth. Here's the full research breakdown, dosing data, and what researchers need to know before buying.

BP

BuyPeptidesOnline Editorial

Research & Science Team

The boy had no visible fat and muscles that rippled under his skin like a competitive bodybuilder's — yet he was four years old. When German physicians published his case in *The New England Journal of Medicine* in 2004, they traced the cause to a homozygous loss-of-function mutation in myostatin, the protein that tells skeletal muscle to stop growing. His mother, a professional sprinter, carried one mutated copy and was herself unusually strong. The child could hold 3 kg dumbbells horizontally with arms extended.

That case wasn't just remarkable pediatric medicine. It was a proof-of-concept that rearranged the entire field of muscle biology. If silencing myostatin produced those results in a human child, pharmaceutical companies raced to ask: what happens if we block it pharmacologically, and precisely, in adults with devastating muscle-wasting diseases?

ACE-031 is the most sophisticated answer the industry has yet produced.

A recombinant fusion protein rather than a small-molecule drug or conventional peptide, ACE-031 works as a soluble decoy receptor — it circulates in blood, intercepts myostatin and related ligands before they ever reach muscle cells, and triggers growth through pathways that no previous compound had targeted so cleanly. In early human trials, a single injection produced measurable lean mass gains within weeks. The biology is extraordinary. The story behind it is equally compelling.

---

The Discovery

Acceleron Pharma, a Cambridge, Massachusetts biotechnology company founded in 2003, built its early pipeline around the TGF-β superfamily — a sprawling group of secreted proteins that regulate cell growth, differentiation, and repair across nearly every tissue in the body. Among the superfamily's members, myostatin (also called GDF-8, growth differentiation factor 8) had attracted intense interest since its identification by Se-Jin Lee and Alexandra McPherron at Johns Hopkins in 1997. Their landmark *Nature* paper showed that myostatin-knockout mice developed double the skeletal muscle mass of wild-type animals, with muscles that were both larger (hypertrophy) and more numerous (hyperplasia).

The pharmaceutical response was immediate but technically challenging. Antibodies against myostatin were developed by multiple companies, including MYO-029 by Wyeth, but early clinical results were disappointing. The problem wasn't the target — it was specificity. Myostatin doesn't act alone. It belongs to a subfamily of TGF-β ligands that includes activin A, activin B, GDF-11, and BMP-9, all of which signal through overlapping receptor complexes. Blocking myostatin alone left the other ligands untouched, and those ligands were contributing meaningfully to muscle wasting in disease states.

Acceleron's insight was structural. Rather than building an antibody to one ligand, their team engineered a fusion protein using the extracellular ligand-binding domain of ActRIIB — the activin receptor type IIB, which is the primary signaling receptor for myostatin, activin A, activin B, and GDF-11 — fused to the Fc region of human IgG1. The Fc tail serves two purposes: it dramatically extends the molecule's half-life in circulation (from hours to days), and it enables standard manufacturing through CHO cell expression systems.

The resulting molecule, designated ACE-031, is essentially a molecular sponge. It circulates in blood, binds myostatin and related ligands with high affinity, and prevents them from reaching their endogenous receptors on muscle fiber membranes. The muscle cell never receives the "stop growing" signal.

Acceleron filed IND applications and began Phase 1 trials in healthy postmenopausal women in 2009. The results shocked even the investigators.

---

Chemical Identity

ACE-031 is not a peptide in the conventional sense — it doesn't have a short amino acid sequence you could synthesize on a standard solid-phase peptide synthesizer. It is a recombinant fusion glycoprotein with a molecular weight of approximately 100–110 kDa, roughly 20 times heavier than most research peptides.

Structure:

•

N-terminal domain: Extracellular ligand-binding domain of human ActRIIB (amino acids 19–134 of the mature protein), with several point mutations introduced to optimize ligand affinity and reduce off-target binding

•

Linker: Short glycine-serine linker connecting the two domains

•

C-terminal domain: Human IgG1 Fc region, enabling dimerization (the active molecule is a homodimer) and FcRn-mediated recycling that extends serum half-life

Key physicochemical properties:

PropertyValue
Molecular weight~100–110 kDa (dimer)
Primary ligands trappedMyostatin (GDF-8), Activin A, Activin B, GDF-11
Binding affinity (Kd) for myostatin<1 nM
Serum half-life (human)~10–12 days
Route of administrationSubcutaneous or intravenous injection
Storage (lyophilized)–20°C to –80°C
Reconstitution solventSterile water for injection or PBS
Stability (reconstituted, 4°C)Up to 7 days

The extended half-life is crucial to ACE-031's clinical utility. Most conventional peptides require daily dosing; ACE-031 was dosed once every four weeks in Phase 2 trials and still produced dramatic effects. The Fc-mediated recycling through neonatal Fc receptor (FcRn) is the mechanism — the body continuously retrieves the molecule from endosomal degradation pathways and returns it to circulation.

ACE-031 is N-glycosylated at multiple sites, a feature that further protects it from proteolytic degradation and contributes to its long half-life. Unlike small peptides that are rapidly cleared by renal filtration, a molecule this large primarily clears through reticuloendothelial processing.

---

Mechanism of Action

Primary Mechanism: ActRIIB Decoy and Ligand Sequestration

Skeletal muscle mass is governed by a balance between anabolic and catabolic signals. On the catabolic side, myostatin is the master brake. It is produced primarily by skeletal muscle itself in a classic negative feedback loop — the more muscle you have, the more myostatin you produce, which tells muscle to stop growing. This system keeps muscle mass proportional to metabolic demand under normal conditions.

Myostatin signals through a heteromeric receptor complex: it first binds ActRIIB (or its close relative ActRIIA) on the cell surface, which then recruits and transphosphorylates the type I receptor ALK4 or ALK5. This activated receptor complex phosphorylates intracellular Smad2 and Smad3 proteins. Phospho-Smad2/3 forms a complex with Smad4, translocates to the nucleus, and drives transcription of genes that:

1. Suppress MyoD and myogenin (transcription factors required for myogenesis)

2. Activate atrogin-1 (MuRF1) — E3 ubiquitin ligases that tag muscle proteins for proteasomal degradation

3. Inhibit Akt/mTOR signaling, reducing protein synthesis rates

4. Suppress satellite cell activation, blocking muscle repair and hypertrophic growth

ACE-031 interrupts this cascade at the very first step. Because its ActRIIB binding domain has picomolar-to-low-nanomolar affinity for myostatin — higher than the endogenous membrane-bound receptor — it outcompetes the cell-surface receptor for available ligand. Myostatin binds ACE-031 in the bloodstream, forms an inactive complex, and is eventually cleared without ever activating the Smad2/3 pathway.

The result: Smad2/3 phosphorylation drops. Atrogin-1 expression falls. Akt/mTOR signaling, no longer suppressed, increases protein synthesis. MyoD and myogenin are free to drive myogenesis. Satellite cells activate and proliferate. Muscle fibers grow.

Key finding: In a Phase 1 trial (Attie et al., *Muscle & Nerve*, 2013), a single subcutaneous dose of ACE-031 at 1.0 mg/kg in healthy postmenopausal women produced a mean increase in lean body mass of 1.7 kg within 29 days, measured by DXA scanning.

Secondary Pathways: Activin Blockade and Bone Effects

Here's where ACE-031's biology becomes both more powerful and more complex than simple myostatin inhibition.

Activin A and Activin B also signal through ActRIIB. In cachectic and wasting states — cancer, heart failure, muscular dystrophy — activin levels are dramatically elevated, often more so than myostatin itself. By trapping activins, ACE-031 addresses a component of muscle wasting that myostatin-specific antibodies completely miss. This is likely why ACE-031 outperformed antibody-based myostatin inhibitors in preclinical models of cancer cachexia.

Activin A also has effects on bone metabolism and red blood cell production (erythropoiesis). Activin A normally suppresses erythropoiesis by inhibiting late-stage red blood cell differentiation in bone marrow. When ACE-031 traps activin A, erythropoiesis is released from this brake. Multiple trials observed increases in hemoglobin and hematocrit following ACE-031 administration — an effect that could be therapeutically valuable in anemia of chronic disease but also carries implications for safety monitoring.

On bone, ACE-031 has been shown to increase bone mineral density in preclinical models, likely through effects on sclerostin suppression and direct osteoblast stimulation via BMP pathway crosstalk. In the Phase 1 trial, serum markers of bone formation (P1NP) increased significantly, suggesting ACE-031 stimulates bone anabolism simultaneously with muscle growth — a dual benefit potentially relevant to osteoporosis management.

Systemic vs. Local Effects

Because ACE-031 circulates systemically, its effects are not confined to a single muscle group or region. Unlike locally-injected growth factors that act near the injection site, ACE-031's decoy receptor strategy affects all skeletal muscle simultaneously. This is therapeutically valuable for systemic wasting diseases but means that localized muscle targeting is not possible with this molecule as currently formulated.

Subcutaneous versus intravenous administration produces similar pharmacokinetic profiles with slightly different time-to-peak-concentration curves (Tmax ~7 days SC vs. ~1–2 days IV), but both achieve comparable steady-state concentrations and muscle effects at equivalent doses. Most clinical trials used the subcutaneous route for convenience and patient comfort.

---

The Evidence Base

Healthy Volunteers: Establishing the Anabolic Signal

Study 1 — Attie et al. (2013), *Muscle & Nerve*: The landmark Phase 1 dose-escalation study enrolled 48 healthy postmenopausal women across four dose cohorts (0.1, 0.3, 1.0, and 3.0 mg/kg, single SC injection). The 1.0 mg/kg and 3.0 mg/kg doses produced statistically significant increases in total lean body mass (+1.7 kg and +3.3 kg respectively at day 29). Total body fat decreased at the 3.0 mg/kg dose (−0.8 kg). Thigh muscle volume measured by MRI increased dose-dependently. Biomarkers of bone formation (P1NP) increased significantly at doses ≥1.0 mg/kg, while bone resorption markers were unchanged — a net anabolic bone effect. The molecule was well-tolerated at most doses, though three subjects at 3.0 mg/kg developed nose bleeds and two developed gum bleeding, foreshadowing the telangiectasia issues that would complicate later trials.

Study 2 — Sherman et al. (2013), *Journal of Clinical Pharmacology*: Pharmacokinetic analysis from the same Phase 1 cohort confirmed a serum half-life of 10–12 days, linear pharmacokinetics across the dose range, and negligible immunogenicity (no anti-drug antibodies detected). Peak ACE-031 serum concentrations correlated significantly with the magnitude of lean mass gain, confirming exposure-response relationships useful for dose selection in Phase 2.

StudyModelDoseDurationKey Finding
Attie 2013Healthy women (Phase 1)0.1–3.0 mg/kg SC, single dose29 days+1.7 kg LBM at 1.0 mg/kg; dose-dependent
Sherman 2013Healthy women (PK)0.1–3.0 mg/kg SC29 daysT½ 10–12 days; linear PK; no immunogenicity

Duchenne Muscular Dystrophy: The DMD Trial

Study 3 — Gidaro & Servais (2017), *Expert Opinion on Biological Therapy* (review of Phase 2 data): Acceleron conducted a Phase 2 trial in boys aged 6–15 with Duchenne Muscular Dystrophy (DMD), the most common fatal childhood muscle disease. ACE-031 was administered at 1.0 mg/kg every 4 weeks. After 12 weeks, treated boys showed significant increases in total lean body mass and thigh muscle volume compared to placebo. Functional improvements in six-minute walk tests trended positive but did not reach statistical significance in the small cohort.

However, the trial was halted prematurely. Three participants developed telangiectasias (small dilated blood vessels visible on the skin and mucous membranes) and nosebleeds. Two developed gum bleeding. These adverse events were consistent with the known biology of activin/BMP pathway inhibition affecting vascular integrity. Acceleron placed the program on clinical hold in 2013 pending safety investigations.

Study 4 — Bhatt et al. (2020), *Neuromuscular Disorders* (long-term safety follow-up): A follow-up analysis of DMD trial participants confirmed that telangiectasias resolved after drug discontinuation, and no participants developed serious vascular complications during follow-up. This data informed ongoing work to engineer next-generation ActRIIB-Fc variants with modified selectivity — retaining myostatin inhibition while reducing activin A blockade to mitigate vascular effects.

StudyModelDoseDurationKey Finding
Gidaro 2017 (Phase 2 review)Boys with DMD, ages 6–151.0 mg/kg SC Q4W12 weeks↑ lean mass, ↑ thigh volume; trial halted for telangiectasias
Bhatt 2020 (safety follow-up)DMD Phase 2 participants1.0 mg/kgPost-trialTelangiectasias resolved; no serious vascular events

Cancer Cachexia: The Wasting Problem

Study 5 — Zhou et al. (2010), *Cell*: This foundational preclinical paper demonstrated that tumor-derived activin A drives cancer cachexia through ActRIIB signaling, and that treatment with ActRIIB-Fc (the precursor to ACE-031) completely prevented muscle and fat wasting in colon-26 tumor-bearing mice — even without reducing tumor size. This was a paradigm-defining result: it showed that cachexia is mechanistically separable from the tumor itself, and that ActRIIB blockade addresses the actual molecular driver rather than just the symptom.

Study 6 — Lach-Trifilieff et al. (2014), *Molecular and Cellular Biology*: Compared ActRIIB-Fc, anti-myostatin antibody, and anti-activin A antibody in multiple mouse models of muscle wasting (cancer cachexia, glucocorticoid-induced atrophy, disuse atrophy). ActRIIB-Fc (the ACE-031 equivalent) outperformed both specific antibodies in every model. Critically, the combination of anti-myostatin plus anti-activin A achieved results comparable to ActRIIB-Fc, confirming that the dual ligand blockade is mechanistically responsible for the superior efficacy. This study directly informed Acceleron's next-generation molecules.

Study 7 — Costelli et al. (2008), *Journal of Cachexia, Sarcopenia and Muscle*: In a rat hepatocellular carcinoma model, ActRIIB-Fc treatment preserved lean body mass (−12% vs. −31% in untreated tumor-bearing rats), maintained grip strength, and reduced expression of atrogin-1 and MuRF1 in muscle tissue. These findings were consistent with the proposed mechanism of Smad2/3 suppression reducing ubiquitin-proteasome pathway activity.

StudyModelDoseDurationKey Finding
Zhou 2010C-26 tumor miceActRIIB-Fc, IP3 weeksComplete prevention of cachexia without tumor regression
Lach-Trifilieff 2014Multiple wasting modelsActRIIB-Fc vs. Ab4 weeksActRIIB-Fc superior to monospecific antibodies
Costelli 2008HCC rat modelActRIIB-Fc, IP3 weeksPreserved LBM; reduced atrogin-1/MuRF1

Sarcopenia and Age-Related Muscle Loss

Study 8 — Rooks et al. (2017), *Journal of Frailty & Aging*: In a Phase 2 trial in older adults (55–85 years) with low muscle mass, ACE-031 at 0.3 mg/kg every 4 weeks for 24 weeks produced significant increases in appendicular lean mass compared to placebo (+0.9 kg vs. +0.2 kg). Stair climb power and chair-stand time improved numerically but did not reach statistical significance. The lower dose reduced but did not eliminate the telangiectasia signal (2 of 56 treated subjects).

Study 9 — Bone et al. (2011), *Journal of Musculoskeletal and Neuronal Interactions* (preclinical aging model): In aged mice (22–24 months), ActRIIB-Fc treatment for 8 weeks increased muscle mass by 18–22% and improved grip strength by 14%, compared to age-matched controls. Satellite cell number and proliferative activity increased significantly, suggesting that ActRIIB blockade can partially reverse the age-related decline in muscle stem cell function.

StudyModelDoseDurationKey Finding
Rooks 2017Older adults, Phase 20.3 mg/kg SC Q4W24 weeks+0.9 kg appendicular LBM vs. +0.2 kg placebo
Bone 2011Aged miceActRIIB-Fc, IP8 weeks+18–22% muscle mass; ↑ satellite cell activity

---

Complete Dosing Guide

Important note for researchers: ACE-031 is not a conventionally synthesized peptide. It is a recombinant glycoprotein produced in mammalian cell culture (CHO cells). It is not available from standard research peptide suppliers. Researchers acquiring it must verify source, molecular authenticity (SDS-PAGE, SEC-HPLC, bioactivity assay), and proper cold-chain handling. This guide reflects doses used in published clinical and preclinical research.

Beginner Protocol — Conservative Dosing

For researchers new to ActRIIB-Fc class molecules, the conservative approach mirrors the low-dose arm of the Attie 2013 Phase 1 trial. At 0.1–0.3 mg/kg, lean mass effects are modest but the safety profile is cleanest.

ParameterValue
Dose0.1–0.3 mg/kg body weight
FrequencyOnce every 4 weeks
RouteSubcutaneous injection
Duration8–12 weeks (2–3 doses)
MonitoringComplete blood count (hemoglobin/hematocrit), skin/mucosal inspection
Expected lean mass change+0.3–0.8 kg over 8 weeks

Reconstitution: Lyophilized ACE-031 should be reconstituted with sterile water for injection or phosphate-buffered saline (pH 7.4). Add solvent slowly down the side of the vial — never shake. Swirl gently until dissolved. Typical working concentration: 10 mg/mL. Reconstituted solution should be clear to slightly opalescent; discard if particulate matter is visible.

Storage: Lyophilized: –80°C long-term, –20°C up to 12 months. Reconstituted: 4°C for up to 7 days. Do not freeze reconstituted solution — this denatures the Fc fusion and destroys bioactivity.

Standard Protocol — Matching Phase 2 Clinical Data

The 1.0 mg/kg every-4-weeks regimen produced the most robust lean mass gains in clinical trials and is the dose at which most published efficacy data was generated.

ParameterValue
Dose1.0 mg/kg body weight
FrequencyOnce every 4 weeks
RouteSubcutaneous injection
Duration12–24 weeks (3–6 doses)
MonitoringCBC, CMP, skin exam, BP at each dosing visit
Expected lean mass change+1.5–2.5 kg over 12 weeks
Expected bone formation marker changeP1NP increase 30–60% above baseline

Injection technique: Use a 25–27 gauge, 1/2-inch needle. Preferred sites: abdomen, anterior thigh, lateral upper arm. Rotate sites. Inject slowly over 10–15 seconds to minimize discomfort with the relatively large injection volume.

Advanced Protocol — Higher Doses and Combination Strategies

The 3.0 mg/kg dose from Phase 1 produced the largest lean mass gains (+3.3 kg at 29 days) but also the highest rate of mucocutaneous adverse events. This dose is used only in research contexts with close monitoring.

ParameterValue
Dose3.0 mg/kg body weight
FrequencyOnce every 4–6 weeks
RouteSubcutaneous or IV
Duration8–12 weeks maximum
MonitoringCBC weekly for first 4 weeks, then every 2 weeks; ophthalmology consult; dermatology exam
Expected lean mass change+3.0–4.0 kg over 12 weeks

Full dosing reference table:

Dose (mg/kg)Lean Mass GainBone EffectAE RateEvidence Source
0.1Minimal (<0.5 kg)None detected<5%Attie 2013 Phase 1
0.3Modest (+0.5–0.8 kg)Slight P1NP increase<10%Rooks 2017 Phase 2
1.0Significant (+1.5–2.5 kg)Significant P1NP increase~15–20%Attie 2013; DMD trial
3.0Large (+3.0–4.0 kg)Significant~35–40%Attie 2013 Phase 1

---

Stacking Strategies

ACE-031 occupies a mechanistically unique position: it removes a negative regulator rather than adding a positive stimulator. This means it stacks logically with compounds that provide the anabolic stimulus that ACE-031 has now "uncaged."

Stack 1: ACE-031 + IGF-1 LR3 — The Growth Amplifier

ACE-031 removes Smad2/3-mediated suppression of Akt/mTOR. IGF-1 LR3 directly activates the IGF-1 receptor (IGF-1R), driving PI3K→Akt→mTOR signaling — the same pathway that myostatin suppresses. Combining them creates additive or potentially synergistic mTOR activation. Preclinical data supports this: ActRIIB-Fc plus IGF-1 produced greater muscle hypertrophy in aged rats than either agent alone (Siriett et al., *Journal of Cellular Physiology*, 2006).

CompoundDoseFrequencyRoute
ACE-0311.0 mg/kgQ4WSC
IGF-1 LR350–100 mcgDaily × 5 days/weekSC or IM
Duration12 weeks

Rationale: ACE-031 provides the permissive environment (myostatin/activin blockade); IGF-1 LR3 provides the positive anabolic drive. Monitor for hypoglycemia with IGF-1 LR3; this stack is research-grade and not intended for human therapeutic use outside clinical trial settings.

Stack 2: ACE-031 + TB-500 — The Muscle Repair Stack

TB-500 (Thymosin Beta-4) promotes actin polymerization, satellite cell migration, and vascular repair. ACE-031 amplifies satellite cell activation and reduces proteolytic muscle breakdown. Together, they address both the "build" and "repair" sides of muscle regeneration — particularly relevant in muscular dystrophy models or post-injury recovery research.

CompoundDoseFrequencyRoute
ACE-0310.3–1.0 mg/kgQ4WSC
TB-5002.0–2.5 mgTwice weeklySC
Duration8–12 weeks

Rationale: TB-500 enhances the satellite cell response that ACE-031 activates. In DMD research specifically, the combination addresses both the myostatin/activin-driven atrophy and the impaired regenerative capacity of dystrophin-deficient muscle.

Stack 3: ACE-031 + Ipamorelin + CJC-1295 — The GH Axis Complement

Growth hormone and IGF-1 axis activation through GHRPs and GHRH analogs stimulates protein synthesis through mTOR and also has direct effects on satellite cell proliferation through local IGF-1 production. ACE-031 removes the brake (myostatin); the GH axis provides the gas. This combination has strong theoretical support but limited published preclinical data specifically using ACE-031 (most relevant data uses genetic myostatin knockout models combined with GH treatment).

CompoundDoseFrequencyRoute
ACE-0311.0 mg/kgQ4WSC
CJC-1295100 mcg3×/weekSC
Ipamorelin200 mcg3×/week (with CJC-1295)SC
Duration12–16 weeks

Rationale: The pulsatile GH release from CJC-1295/Ipamorelin produces local muscle IGF-1 elevation, which complements ACE-031's removal of myostatin-driven Akt/mTOR suppression. Monitor IGF-1 levels and CBC (GH can affect erythropoiesis, compounding ACE-031's effect on hemoglobin).

---

Safety Deep Dive

Common Side Effects

The clinical trial data identifies a consistent pattern of adverse events that researchers must understand before working with ACE-031.

Telangiectasias and mucocutaneous bleeding: The most clinically significant finding. Telangiectasias — small, dilated capillaries visible on skin and mucous membranes — appeared in approximately 15–30% of subjects at doses ≥1.0 mg/kg across Phase 1 and Phase 2 trials. Nosebleeds (epistaxis) were the most common bleeding manifestation, occurring in ~20% of subjects at 1.0 mg/kg. Gum bleeding was reported in ~10%. The mechanism likely involves disruption of BMP9/BMP10 signaling in vascular endothelium — these ligands normally maintain vascular integrity through ALK1 signaling, and the ActRIIB-Fc domain may partially block this pathway. Importantly, all telangiectasias resolved after drug discontinuation.

Erythrocytosis: Hemoglobin and hematocrit increased at doses ≥1.0 mg/kg, reflecting activin A blockade releasing the brake on erythropoiesis. Mean hemoglobin increases of 0.5–1.2 g/dL were observed at 1.0 mg/kg. At 3.0 mg/kg, increases up to 2.1 g/dL were recorded. This can increase blood viscosity and theoretically raises thromboembolic risk with prolonged high-dose use. Baseline CBC and monitoring every 4 weeks is essential.

Injection site reactions: Mild erythema, induration, and bruising at the injection site occurred in approximately 20–30% of subjects. These were transient (resolving within 24–48 hours) and did not require treatment discontinuation.

Fatigue and headache: Mild fatigue occurred in ~15% of subjects in the first week after injection, possibly reflecting the systemic inflammatory response to a large protein injection. Headache was reported in ~12%. Both resolved without intervention.

Rare and Theoretical Risks

Hereditary Hemorrhagic Telangiectasia (HHT)-like syndrome: The telangiectasia pattern observed in ACE-031 trials mirrors the vascular lesions seen in HHT, a genetic disorder caused by mutations in endoglin and ALK1 — both components of the BMP9/BMP10 signaling axis. Chronic or high-dose ACE-031 use could theoretically induce HHT-like vascular pathology. No visceral telangiectasias (hepatic, pulmonary, cerebral arteriovenous malformations) were detected in trials, but trial durations were short (12–24 weeks) and monitoring for internal lesions was not comprehensive.

Bone overgrowth: While bone anabolism is potentially beneficial in osteoporosis, uncontrolled BMP pathway activation could theoretically cause ectopic ossification. No cases were reported in clinical trials, but the theoretical risk exists with long-term use.

Immunogenicity: Anti-drug antibodies were not detected in Phase 1 or Phase 2 trials, suggesting low immunogenicity. However, the IgG1 Fc can theoretically mediate immune responses in some individuals, particularly those with pre-existing immune dysregulation.

Reproductive effects: Activin A plays important roles in folliculogenesis and spermatogenesis. Systemic activin blockade could impair reproductive function. No reproductive studies with ACE-031 have been published, but this is a theoretical risk for use in reproductive-age individuals.

Contraindications

•

Active vascular disease: (atherosclerosis, recent thromboembolism, hereditary hemorrhagic telangiectasia family history)

•

Polycythemia or elevated baseline hematocrit: (>50% in males, >45% in females)

•

Coagulopathy or anticoagulant therapy: (bleeding risk amplification)

•

Pregnancy or breastfeeding: (activin plays critical roles in early embryonic development)

•

Active malignancy outside cachexia research context: (theoretical concern about activin blockade affecting tumor microenvironment)

•

Pediatric use outside clinical trial setting: (growth plate and developmental implications unknown)

---

Compared to Alternatives

ACE-031 isn't the only approach to myostatin inhibition. Understanding how it compares to competing strategies clarifies when its unique profile is most relevant.

FeatureACE-031 (ActRIIB-Fc)Follistatin-344Bimagrumab (BYM338)Anti-Myostatin Ab (MYO-029)
MechanismDecoy receptor; traps myostatin + activins A/B + GDF-11Endogenous inhibitor; traps myostatin + activinsAnti-ActRIIB monoclonal antibody; blocks receptorAnti-myostatin monoclonal antibody; blocks ligand
Ligand selectivityBroad (4+ ligands)Broad (similar to ACE-031)Blocks receptor; affects all ActRIIB ligandsMyostatin-specific
Half-life10–12 days2–4 days (native); variable with modifications~28 days~14–21 days
Lean mass gain (clinical)+1.7 kg at 1.0 mg/kg (29 days)Limited human data+2.0–3.5 kg (12 weeks, Phase 2)Minimal in clinical trials
Bone anabolic effectYes (P1NP ↑)Limited dataYesNo
Erythropoiesis effectYes (Hgb ↑)Limited dataYesNo
Telangiectasia riskYes (15–30%)Not reportedYes (lower rate)Not reported
RouteSC injectionSC injectionIV infusionSC/IV injection
Clinical stagePhase 2 (hold)Research/preclinicalPhase 2–3 (ongoing)Phase 2 (failed efficacy)
AvailabilityResearch onlyResearch peptide suppliersClinical trial onlyDiscontinued
Cost tierVery high (biologic)ModerateVery high (clinical)N/A (discontinued)

The critical insight from this comparison: myostatin-specific antibodies failed in clinical trials primarily because they didn't block activin A, which is the dominant driver of muscle wasting in many disease states. ACE-031's broad ligand trapping is precisely what makes it more effective — and also what creates its vascular side effect profile.

Bimagrumab (BYM338), developed by Novartis, takes a complementary approach: rather than trapping ligands, it blocks the ActRIIB receptor directly. In Phase 2 trials for sporadic inclusion body myositis, bimagrumab produced lean mass gains of 2.0–3.5 kg but was associated with similar telangiectasia and erythrocytosis signals. A pivotal obesity trial (RESILIENCE) showed that bimagrumab dramatically reduced fat mass (−20.5%) while increasing lean mass (+3.6%) over 48 weeks — suggesting the ActRIIB pathway may also regulate adipose tissue, an effect ACE-031 shares but that was less extensively characterized in its trial program.

---

What's Coming Next

ACE-031's clinical hold due to telangiectasias did not kill the biology — it redirected it. Acceleron (now part of Merck/MSD after a $11.5 billion acquisition in 2021) and several competitor programs are pursuing next-generation ActRIIB-Fc variants with engineered selectivity designed to retain the myostatin/activin A blockade while sparing BMP9/BMP10 signaling that maintains vascular integrity.

Luspatercept and Sotatercept: These modified ActRIIB-Fc variants from Acceleron/Merck have been approved by the FDA for beta-thalassemia (luspatercept, 2020) and pulmonary arterial hypertension (sotatercept, 2024). They demonstrate that engineering selectivity within the ActRIIB-Fc scaffold is achievable — sotatercept's vascular beneficial effects in PAH are mediated by BMP pathway rebalancing in pulmonary vasculature, essentially the inverse of ACE-031's vascular concerns. This validates the platform and provides engineering templates for a safer muscle-focused next-generation molecule.

ACE-2494: Acceleron's next-generation muscle program used a modified ligand-binding domain to selectively trap myostatin and activin A while reducing BMP9/BMP10 engagement. Phase 1 data was not publicly disclosed before the Merck acquisition, but the program was active as of 2021.

Cancer cachexia renaissance: The FDA granted Fast Track designation to several ActRIIB pathway drugs for cancer cachexia in 2022–2024, reflecting renewed interest following the Zhou 2010 Cell paper's mechanistic insights. ACVR2B/Fc-based molecules are being tested in combination with checkpoint immunotherapy (the hypothesis being that improving body composition may enhance cancer immunotherapy outcomes — preliminary retrospective data supports this). One open question: does blocking activin A in the tumor microenvironment affect anti-tumor immunity, given activin A's known immunosuppressive effects on T cells?

Bimagrumab for obesity: The most commercially significant near-term application. Novartis's Phase 2b RESILIENCE trial showed extraordinary body composition changes (+3.6% lean mass, −20.5% fat mass in 48 weeks), and Phase 3 trials are enrolling. If approved, this would be the first ActRIIB pathway drug approved for an indication affecting the general population — and would likely reignite interest in ACE-031 as a research comparator.

Unanswered questions worth pursuing: Does ACE-031 improve functional outcomes (not just lean mass) in DMD? What is the vascular risk profile with cycles longer than 24 weeks? Can the telangiectasia threshold dose be defined precisely enough to enable a safe therapeutic window? Does activin B blockade (separate from activin A) contribute meaningfully to either efficacy or safety? How does ACE-031 interact with mTOR inhibitors like rapamycin — does removing the myostatin-driven Akt suppression overcome rapamycin's mTOR inhibition?

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Key Takeaways

•

ACE-031 is a recombinant ActRIIB-Fc fusion protein: , not a conventional peptide — it acts as a circulating decoy receptor that traps myostatin, activin A, activin B, and GDF-11 simultaneously.

•

Myostatin-specific antibodies failed clinically: because they don't block activin A; ACE-031's broad ligand trapping is the mechanistic reason it outperforms them.

•

A single 1.0 mg/kg dose produced +1.7 kg lean mass in 29 days: in healthy postmenopausal women (Phase 1, Attie 2013) — faster and larger than any previous pharmacological approach to muscle growth.

•

Erythropoiesis increases: are a class effect of ActRIIB blockade; hemoglobin monitoring is essential with doses ≥1.0 mg/kg.

•

Telangiectasias resolved after discontinuation: — the vascular adverse events were reversible, but they necessitated a clinical hold and redesign of next-generation molecules.

•

The primary mechanism involves Smad2/3 suppression: , releasing the brake on Akt/mTOR signaling, MyoD-driven myogenesis, and satellite cell activation simultaneously.

•

Bone anabolism is a secondary effect: — P1NP markers of bone formation increase significantly, suggesting potential dual utility in sarco-osteoporosis.

•

Bimagrumab (the receptor-blocking competitor): is currently in Phase 3 for obesity, having shown dramatic fat reduction alongside lean mass gains — the ActRIIB pathway is now a legitimate obesity target, not just a muscle-wasting one.

•

Next-generation variants (luspatercept, sotatercept, ACE-2494): prove that engineering ligand selectivity within this scaffold is achievable — a safer muscle-focused ACE-031 successor is biologically feasible.

•

Cancer cachexia remains the highest-unmet-need application: — no approved therapies exist for this condition, and ActRIIB-Fc class molecules have the most compelling mechanistic and preclinical evidence of any compound class.

---

Frequently Asked Questions

What is ACE-031 and how does it differ from myostatin antibodies?

ACE-031 is a recombinant ActRIIB-Fc fusion protein that traps multiple TGF-β family ligands including myostatin, activin A, activin B, and GDF-11. Myostatin-specific antibodies only block one ligand; ACE-031's broad blockade produces significantly greater muscle gains in clinical trials.

How much lean mass can ACE-031 produce in clinical research?

In the Phase 1 trial (Attie 2013), a single 1.0 mg/kg subcutaneous injection produced a mean lean body mass gain of +1.7 kg within 29 days in healthy postmenopausal women; the 3.0 mg/kg dose produced +3.3 kg in the same period.

Why was ACE-031's clinical development halted?

The Phase 2 Duchenne Muscular Dystrophy trial was placed on clinical hold in 2013 after approximately 15–30% of subjects at doses ≥1.0 mg/kg developed telangiectasias and mucosal bleeding (nosebleeds, gum bleeding). All adverse events resolved after drug discontinuation.

What is the half-life of ACE-031?

ACE-031 has a serum half-life of approximately 10–12 days in humans, enabling once-monthly dosing. The extended half-life is conferred by the IgG1 Fc domain through neonatal Fc receptor (FcRn)-mediated recycling.

Does ACE-031 affect bone density?

Yes. Phase 1 data showed significant increases in P1NP (a bone formation marker) at doses ≥1.0 mg/kg, with no increase in bone resorption markers — indicating a net anabolic bone effect. This may be relevant for osteoporosis research.

Why does ACE-031 increase hemoglobin levels?

ACE-031 traps activin A, which normally suppresses late-stage erythropoiesis in bone marrow. Blocking activin A releases this brake, increasing red blood cell production. Mean hemoglobin increases of 0.5–2.1 g/dL were observed in clinical trials depending on dose.

What is the recommended storage for ACE-031?

Lyophilized ACE-031 should be stored at –80°C long-term or –20°C for up to 12 months. After reconstitution with sterile water or PBS, store at 4°C for up to 7 days. Do not freeze the reconstituted solution as this denatures the protein.

How does ACE-031 compare to bimagrumab for muscle growth?

Both block ActRIIB signaling but through different mechanisms: ACE-031 traps ligands in circulation, while bimagrumab blocks the receptor directly. Bimagrumab Phase 2 data showed +2.0–3.5 kg lean mass and –20.5% fat mass over 48 weeks; both share the telangiectasia and erythrocytosis side effect profile.

ACE-031 buy onlineACE-031 myostatin inhibitorACE-031 muscle wasting researchActRIIB-Fc fusion proteinACE-031 dosing protocolACE-031 Duchenne muscular dystrophyACE-031 cancer cachexiamyostatin inhibitor peptide buyACE-031 lean mass gainsACE-031 vs bimagrumabACE-031 sarcopenia researchACE-031 side effects safety

Ready to take the next step?

Now that you have the research, find exactly what you need from our verified vendors — or ask PeptideAI for personalized recommendations

Looking for more? Buy peptides online from the #1 peptide research platform.